Trillium Therapeutics Inc Quick Ratio (TRIL) starting from the third quarter 2021 to third quarter 2019, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Trillium Therapeutics Inc   (NASDAQ: TRIL)

Trillium Therapeutics Inc 's Quick Ratio

TRIL's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the third quarter 2021, Quick Ratio fell to 5.3 above Trillium Therapeutics Inc average.

Within Major Pharmaceutical Preparations industry 341 other companies have achieved higher Quick Ratio than Trillium Therapeutics Inc in third quarter 2021. While Quick Ratio total ranking in the third quarter 2021 has deteriorated compared to the prior quarter from 552 to 1223.

Explain Quick Ratio?
How much Cash & cash equivalents TRIL´s has?
What are TRIL´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

TRIL Quick Ratio (Sep 30 2021)
Q3		 (Jun 30 2021)
Q2		 (Mar 31 2021)
Q1		 (Dec 31 2020)
Q4		 (Dec 31 2019)
Q3
Y / Y Current Liabilities Change -16.63 % -12.34 % -10.58 % 24.59 % 7.12 %
Y / Y Cash & cash equivalent Change 224.75 % 1092.67 % 1751.19 % 1465.49 % 87.61 %
Quick Ratio MRQ 5.3 14.67 22.32 13.55 1.36
TRIL's Total Ranking # 1223 # 552 # 297 # 290 #
Seq. Current Liabilities Change 48.47 % -1.96 % -28.23 % -20.19 % 56.1 %
Seq. Cash & cash equivalent Change -46.34 % -35.57 % 18.25 % 694.46 % 97.05 %



Quick Ratio third quarter 2021 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 342
Healthcare Sector # 582
Overall Market # 1223


Quick Ratio Statistics
High Average Low
22.32 5.21 0.65
(Mar 31 2021)   (Dec 31 2018)




Financial Statements
Trillium Therapeutics Inc 's Current Liabilities $ 18 Millions Visit TRIL's Balance sheet
Trillium Therapeutics Inc 's Cash & cash equivalent $ 93 Millions Visit TRIL's Balance sheet
Source of TRIL's Sales Visit TRIL's Sales by Geography


Cumulative Trillium Therapeutics Inc 's Quick Ratio

TRIL's Quick Ratio for the trailling 12 Months

TRIL Quick Ratio

 (Sep 30 2021)
12 Months		 (Jun 30 2021)
12 Months		 (Mar 31 2021)
12 Months		 (Dec 31 2020)
12 Months		 (Dec 31 2019)
12 Months
Y / Y Current Liabilities TTM Growth -5.32 % 2.7 % 11.57 % 21.08 % 22.4 %
Y / Y Cash & cash equivalent TTM Growth 956.08 % 1086.67 % 796.06 % 363.01 % 14.72 %
Quick Ratio TTM 13.11 11.32 8.52 4.4 1.17
Total Ranking TTM # 3899 # 241 # 130 # 488 #
Seq. Current Liabilities TTM Growth -5.67 % -2.62 % -2.2 % 5.39 % 2.33 %
Seq. Cash & cash equivalent TTM Growth 9.21 % 29.42 % 89.23 % 294.84 % 22.72 %

Quick ratio ranking by company, industry and sector >> Back to TRIL Financial Strength Comparisons >> Go to Compare TRIL Quick Ratio to its Competitors

On the trailing twelve months basis TRIL Cash & cash equivalent more than doubled by 224.75 % in Q3 2021 year on year, while Current Liabilities soared to $18 millions, this led to increase in in Trillium Therapeutics Inc 's Quick Ratio to 13.11, above TRIL average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 484 other companies have achieved higher Quick Ratio than Trillium Therapeutics Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2021 from 241 to 3899.

Explain Quick Ratio?
How much Cash & cash equivalents TRIL´s has?
What are TRIL´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 485
Healthcare Sector # 930
Within the Market # 3899


trailing twelve months Quick Ratio Statistics
High Average Low
15.08 5.53 1.08
(Sep 30 2021)   (Dec 31 2019)




Companies with similar Quick Ratio in the quarter ending Sep 30 2021, within Major Pharmaceutical Preparations Industry Quick RatioSep 30 2021 MRQ Cash & cash equivalentSep 30 2021 MRQ Current Liabilities
Royalty Pharma Plc  14.57 $ 2,113.569  Millions$ 145.055  Millions
Hepion Pharmaceuticals Inc   14.53 $ 98.731  Millions$ 6.797  Millions
Rezolute Inc   14.35 $ 37.292  Millions$ 2.598  Millions
Rhythm Pharmaceuticals Inc   14.35 $ 328.354  Millions$ 22.879  Millions
Oramed Pharmaceuticals Inc  14.34 $ 111.116  Millions$ 7.748  Millions
Enliven Therapeutics Inc   14.31 $ 102.839  Millions$ 7.188  Millions
Synlogic Inc   14.17 $ 150.054  Millions$ 10.591  Millions
Korro Bio Inc   14.12 $ 148.074  Millions$ 10.485  Millions
Inozyme Pharma Inc   14.01 $ 125.283  Millions$ 8.943  Millions
Whitehawk Therapeutics Inc   13.95 $ 161.375  Millions$ 11.567  Millions
Carisma Therapeutics Inc   13.91 $ 175.236  Millions$ 12.594  Millions
Cormedix Inc   13.81 $ 71.969  Millions$ 5.211  Millions
Rain Enhancement Technologies Holdco Inc   13.76 $ 150.081  Millions$ 10.904  Millions
Capricor Therapeutics inc   13.67 $ 40.839  Millions$ 2.988  Millions
Otonomy Inc   13.60 $ 87.096  Millions$ 6.402  Millions
Gain Therapeutics inc  13.31 $ 40.979  Millions$ 3.079  Millions
Stealth Biotherapeutics Corp  13.30 $ 47.135  Millions$ 3.545  Millions
Cellectar Biosciences Inc   13.30 $ 40.345  Millions$ 3.034  Millions
Praxis Precision Medicines Inc   13.06 $ 314.370  Millions$ 24.073  Millions
Arbutus Biopharma Corp  12.98 $ 112.224  Millions$ 8.643  Millions
Immunome Inc   12.83 $ 56.243  Millions$ 4.384  Millions
Vanda Pharmaceuticals Inc   12.76 $ 405.968  Millions$ 31.820  Millions
Igm Biosciences Inc   12.69 $ 259.511  Millions$ 20.451  Millions
Neubase Therapeutics inc   12.67 $ 53.147  Millions$ 4.194  Millions
Pulmatrix Inc   12.63 $ 53.491  Millions$ 4.234  Millions
Plx Pharma Inc   12.57 $ 82.554  Millions$ 6.566  Millions
Neximmune Inc   12.55 $ 93.243  Millions$ 7.433  Millions
Clene Inc   12.53 $ 60.552  Millions$ 4.831  Millions
Allakos Inc   12.45 $ 505.607  Millions$ 40.623  Millions
Zai Lab Limited  12.39 $ 1,568.498  Millions$ 126.606  Millions

Date modified: 2026-09-26T07:33:43+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.